Perforomist Inhalation Solution data to be presented today at American Thoracic Society conference

... resulted in improved pulmonary function, dyspnea (shortness of breath) and rescue medication use ... significant improvements in pulmonary function, dyspnea and rescue medication use were seen over ... was measured by serial spirometry, transitional dyspnea index (TDI), rescue albuterol use and the St. ...

Perforomist(R) Inhalation Solution Data in Patients With Moderate to Severe COPD to Be Presented at the International Conference of the American Thoracic Society

... resulted in improved pulmonary function, dyspnea (shortness of breath) and rescue medication use ... significant improvements in pulmonary function, dyspnea and rescue medication use were seen over ... was measured by serial spirometry, transitional dyspnea index (TDI), rescue albuterol use and the St. ...

Study Showed ALIMTA(R) (pemetrexed for injection) Improved Survival in Certain Types of Non-Small Cell Lung Cancer

... cardiac ischemia (3 vs 1); anorexia (5 vs 8); dyspnea (18 vs 26); and chest pain (7 vs 8). The most ... (20 vs 23); edema (19 vs 24); dyspnea (72 vs 74); chest pain (38 vs ... (28 vs 9); diarrhea (26 vs 16); dyspnea (66 vs 62); chest pain (40 vs 30); and rash (22 ...

Concomitant use of Perforomist & tiotropium -- significant improvements -- COPD

... Fumarate to Tiotropium Treatment Relieves dyspnea and Symptoms in COPD Patients in a poster session ... were measured by the baseline/transitional dyspnea index, daily recording of COPD symptoms, rescue ... significance between the mean transitional dyspnea index scores in the Perforomist/TIO and ...

ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection)

... 3); cardiac ischemia (3 vs 1); anorexia (5 vs 8); dyspnea (18 vs 26); and chest pain (7 vs 8). The most ... (20 vs 23); edema (19 vs 24); dyspnea (72 vs 74); chest pain (38 vs ... (28 vs 9); diarrhea (26 vs 16); dyspnea (66 vs 62); chest pain (40 vs 30); and rash (22 ...

Ambulatory oxygen rarely a benefit in COPD patients without resting hypoxemia

... use of oxygen to relieve day-to-day dyspnea in patients with COPD without resting hypoxemia. ... in the walk test, but no improvement in their dyspnea scores or on their questionnaires. When assessed ... controls, four patients showed improvement in the dyspnea scores with oxygen, and only one was identified ...

Data on VELCADE(R) (Bortezomib) for Injection Based Therapies to be Presented at the International Myeloma Workshop

... (23%), headache, paresthesia and dysesthesia and headache (each 22%), dyspnea (21%), cough and insomnia (each 20%), rash (18%), arthralgia (17%), ... (7%), pyrexia (6%), diarrhea (5%), vomiting (4%), and nausea, dehydration, dyspnea and thrombocytopenia (each 3%). For more information about VELCADE ...

New research about chronic lung disease presented at CHEST 2008

... with American ginseng for fatigue, morphine sulfate for control of severe dyspnea and pain, licorice root powder for control of severe coughing spells, and ... used as nebulizer in two patients, was effective in the control of marked dyspnea and pain. One patient lived 4 months using the supportive therapy, while ...

New critical care research presented at CHEST 2008

... with American ginseng for fatigue, morphine sulfate for control of severe dyspnea and pain, licorice root powder for control of severe coughing spells, and ... used as nebulizer in two patients, was effective in the control of marked dyspnea and pain. One patient lived 4 months using the supportive therapy, while ...

CHEST 2008: Featured abstracts

... with American ginseng for fatigue, morphine sulfate for control of severe dyspnea and pain, licorice root powder for control of severe coughing spells, and ... used as nebulizer in two patients, was effective in the control of marked dyspnea and pain. One patient lived 4 months using the supportive therapy, while ...

New lung cancer research presented at CHEST 2008

... with American ginseng for fatigue, morphine sulfate for control of severe dyspnea and pain, licorice root powder for control of severe coughing spells, and ... used as nebulizer in two patients, was effective in the control of marked dyspnea and pain. One patient lived 4 months using the supportive therapy, while ...

FDA Approves VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma

... back pain (17% vs 18%), pneumonia (16% vs 11%), dizziness (16% vs 11%), dyspnea (15% vs 13%), headache (14% vs 10%), pain in extremity (14% vs 9%), ... (7%), pyrexia (6%), diarrhea (5%), vomiting (4%), and nausea, dehydration, dyspnea and thrombocytopenia (each 3%). About Multiple Myeloma Multiple ...

AMITIZA 8 mcg now available to treat irritable bowel syndrome

... if the diarrhea becomes severe. Patients taking AMITIZA may experience dyspnea within an hour of first dose. This symptom generally resolves within three hours, but may recur with repeat dosing. Patients who experience dyspnea should inform their physician. In clinical trials of AMITIZA (24 mcg) ...

Clinical Trial Data for Perforomist(TM) Inhalation Solution to be Presented at ATS on May 20, 2008

... Toronto Convention Center. One of the presentations details the effects on dyspnea and other COPD symptoms of using Perforomist(TM) Inhalation Solution, ... of Nebulized Formoterol Fumarate to Tiotropium Treatment Relieves dyspnea and Symptoms in COPD Patients," Poster Board #F4 -- "Dose-Ranging Study ...

Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer

... stomatitis (41 percent vs 15 percent), vomiting (33 percent vs 44 percent), diarrhea (21 percent vs 35 percent), anorexia (20 percent vs 22 percent), dyspnea (15 percent vs 23 percent), HFS (51 percent vs 1 percent), and rash (29 percent vs 12 percent) In addition, 19 percent vs 52.3 percent ...

New Shape-HF™ Cardiopulmonary Testing System to be on Display at 2009 American Association of Heart Failure Nurses Annual Meeting

... patient functional capacity, monitoring their response to therapy and predicting outcome. Shape-HF™ is designed to quantify the severity of dyspnea on exertion and fatigue and evaluate the interaction between the heart, lungs, and other organ systems. This makes it possible to evaluate therapy ...

Recognizing signs and symptoms of acute HF

... patients peripheral oedema (in 35%) cough (in 33%) breathing difficulty when lying flat (orthopnea, in 30%) chest pain (in 29%) nocturnal dyspnea (in 28%) fatigue (in 17%) palpitations (in 7%) Shortness of breath, said Professor Follath, is by far the most common presenting symptom, and ...

Healthier Lifestyle Can Cut COPD Symptoms

... exercise capacity, dyspnea, handgrip force and fat free mass index. After 24 months, significant improvements remained in exercise capacity, dyspnea and disease-specific quality of life. During the two-year study, the overall cost per patient was about $3,686 more for the intervention group. ...

Lifestyle program for patients with COPD is health and cost effective

... and fat free mass index. After two years improvements in exercise capacity remained significant, as were improvements over the entire period in dyspnea (MRC) and disease-specific quality of life. Furthermore, perceived effectivenessthe patients' subjective evaluation of the benefits of the program ...

Important Data Presented on Independent Predictors of Mortality in Patients With Idiopathic Pulmonary Fibrosis

... of one-year mortality included age, baseline percent predicted diffusing capacity (DLCO), baseline FVC, history of respiratory hospitalization, dyspnea score (as measured by the University of California at San Diego Shortness of Breath Questionnaire) and 24-week change in patient-reported ...

BioCryst Pharmaceuticals Announces Presentation of Forodesine Data at the 45th Annual Meeting of the American Society of Clinical Oncology

... treatment for 12 or more months, the most frequent adverse events were nausea (44 percent), fatigue (22 percent), peripheral edema (22 percent), dyspnea (22 percent) and urinary casts (22 percent). Grade 3 or higher adverse events were diffuse large B-cell lymphoma and peripheral edema. There were ...

Perforomist Inhalation Solution data to be presented at American Thoracic Society conference

... Diego. In one analysis, use of Perforomist Inhalation Solution, when added to maintenance tiotropium, resulted in improved pulmonary function, dyspnea (shortness of breath) and rescue medication use versus treatment with tiotropium alone. In a second study, patient satisfaction increased in those ...

Dey, L.P. Highlights Perforomist(R) Inhalation Solution Data to Be Presented at the International Conference of the American Thoracic Society

... Diego. In one analysis, use of Perforomist Inhalation Solution, when added to maintenance tiotropium, resulted in improved pulmonary function, dyspnea (shortness of breath) and rescue medication use versus treatment with tiotropium alone. In a second study, patient satisfaction increased in those ...

Aplenzin(TM), the Only Single Tablet Once-Daily Treatment for Depression at All Doses, Now Available in the United States

... and confusion have been reported with bupropion. Anaphylactoid reactions characterized by symptoms such as pruritus, urticaria, angioedema, and dyspnea requiring medical treatment have been reported in clinical trials with bupropion. There have been reports of hypertension, in some cases severe, in ...

United States Joins Suits Against Scios and Johnson & Johnson

... In August 2001, the FDA approved Natrecor for "the intravenous treatment of patients with acutely decompensated congestive heart failure who have dyspnea [shortness of breath] at rest or with minimal activity." The study upon which this approval was based involved hospitalized patients who had severe ...

COPD patients benefit more from pulmonary rehab in earlier stages

... COPD who completed an eight-week course of PR. Each patient was evaluated at the beginning and the conclusion of the course for exercise capacity, dyspnea in daily activities, such as walking and carrying groceries, fatigue, quality of life, and other indices of health. The researchers then compared the ...

Bayer Announces Availability of Reformulated Liquid Leukine(R)

... leak syndrome, pleural and or/pericardial effusion, supraventricular tachycardia, sequestration of granulocytes in the pulmonary circulation and dyspnea have been reported in patients after Leukine administration. Leukine has induced the elevation of serum creatinine or bilirubin and hepatic enzymes ...

Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients

... during the studies. The most commonly reported SAEs included pneumonia (7%), pyrexia (6%), diarrhea (5%), vomiting (4%), and nausea, dehydration, dyspnea and thrombocytopenia (each 3%). Adverse events thought by the investigator to be drug-related and leading to discontinuation occurred in 22% of ...

New York Methodist Hospital to study airway bypass treatment for emphysema

... Stent - manufactured by Broncus Technologies, Inc. - to allow the trapped air in the lung to escape. Patients could see an immediate improvement in dyspnea (shortness of breath). "The airway bypass procedure could be an excellent option for those who would possibly spend years on a lung transplant ...

Millennium and Harvard Medical School Sign Cooperative Agreement for Research in Novel Field of Cancer Biology

... during the studies. The most commonly reported SAEs included pneumonia (7%), pyrexia (6%), diarrhea (5%), vomiting (4%), and nausea, dehydration, dyspnea and thrombocytopenia (each 3%). Adverse events thought by the investigator to be drug-related and leading to discontinuation occurred in 22% of ...

Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma

... during the studies. The most commonly reported SAEs included pneumonia (7%), pyrexia (6%), diarrhea (5%), vomiting (4%), and nausea, dehydration, dyspnea and thrombocytopenia (each 3%). Adverse events thought by the investigator to be drug-related and leading to discontinuation occurred in 22% of ...

VELCADE(R) (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation in IFM Phase III Front-Line Multiple Myeloma Trial

... during the studies. The most commonly reported SAEs included pneumonia (7%), pyrexia (6%), diarrhea (5%), vomiting (4%), and nausea, dehydration, dyspnea and thrombocytopenia (each 3%). Adverse events thought by the investigator to be drug-related and leading to discontinuation occurred in 22% of ...

Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma

... during the studies. The most commonly reported SAEs included pneumonia (7%), pyrexia (6%), diarrhea (5%), vomiting (4%), and nausea, dehydration, dyspnea and thrombocytopenia (each 3%). Adverse events thought by the investigator to be drug-related and leading to discontinuation occurred in 22% of ...

Highest Reported Complete Remission Rate of 35 Percent Achieved in a Phase III Front-Line Multiple Myeloma Trial With Velcade(R) (Bortezomib) for Injection Based Therapy

... during the studies. The most commonly reported SAEs included pneumonia (7%), pyrexia (6%), diarrhea (5%), vomiting (4%), and nausea, dehydration, dyspnea and thrombocytopenia (each 3%). Adverse events thought by the investigator to be drug-related and leading to discontinuation occurred in 22% of ...

First in the World Live Case Using New Technology Demonstrates Shorter Procedure Time

... worsened to persistent atrial fibrillation, defined as AF which is sustained beyond seven days. He has suffered from episodic heart palpitations and dyspnea -- all common symptoms of this arrhythmia. "I would often be out of breath and sometimes feel my heart beating much faster than normal," said the ...

Triumph-1 Trial of Viveta in Pulmonary Arterial Hypertension Meets Primary Endpoint

... an increase in median 6MW distance of approximately 18 meters (p Preliminary analysis of other secondary efficacy measures, including change in Borg dyspnea Scale rating (shortness of breath test), NYHA functional class, time to clinical worsening (as defined by death, transplant, atrial septostomy, ...

ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan

... (n=274), respectively, were fatigue (89%, 76%), rash/desquamation (89%, 16%), abdominal pain (59%, 52%), pain-other (51%, 34%), dry skin (49%, 11%), dyspnea (48%, 43%), constipation (46%, 38%), pruritus (40%, 8%), diarrhea (39%, 20%), vomiting (37%, 29%), infection without neutropenia (35%, 17%), headache ...

FDA Expands VELCADE(R) (Bortezomib) for Injection Label for Patients with Multiple Myeloma

... during the studies. The most commonly reported SAEs included pneumonia (7%), pyrexia (6%), diarrhea (5%), vomiting (4%), and nausea, dehydration, dyspnea and thrombocytopenia (each 3%). Adverse events thought by the investigator to be drug-related and leading to discontinuation occurred in 22% of ...

Experts Offer Tips on Lung Cancer Prevention

... with cancer. Massage therapy is recommended as a way to reduce anxiety and pain. Acupuncture is recommended for patients experiencing fatigue, dyspnea and chemo-induced neuropathy. Acupuncture is also recommended for people whose nausea, vomiting or pain is poorly controlled. Electrostimulation ...